Aduro Biotech, Inc. (NASDAQ:ADRO) insider Stephen T. Isaacs sold 19,800 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $7.97, for a total transaction of $157,806.00. Following the completion of the sale, the insider now owns 190,321 shares in the company, valued at $1,516,858.37. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Aduro Biotech, Inc. (ADRO) traded up $0.30 during mid-day trading on Tuesday, hitting $8.25. 824,100 shares of the stock were exchanged, compared to its average volume of 402,670. Aduro Biotech, Inc. has a twelve month low of $6.01 and a twelve month high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. During the same quarter in the prior year, the firm earned ($0.54) EPS. The firm’s revenue was up .0% compared to the same quarter last year. analysts forecast that Aduro Biotech, Inc. will post -1.28 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Aduro Biotech, Inc. (ADRO) Insider Stephen T. Isaacs Sells 19,800 Shares” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.themarketsdaily.com/2017/11/15/aduro-biotech-inc-adro-insider-stephen-t-isaacs-sells-19800-shares.html.
A number of analysts recently commented on the stock. BidaskClub downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Cowen and Company assumed coverage on shares of Aduro Biotech in a report on Tuesday, July 18th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $19.14.
Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in shares of Aduro Biotech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Aduro Biotech during the third quarter valued at approximately $127,000. Tudor Investment Corp ET AL raised its holdings in shares of Aduro Biotech by 34.8% during the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,984 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Aduro Biotech by 15.9% during the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 2,119 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Aduro Biotech during the third quarter valued at approximately $167,000. Institutional investors and hedge funds own 33.63% of the company’s stock.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.